Metamizole sodium is a non-steroidal anti-inflammatory drug (NSAID), commonly used in many countries as a powerful painkiller and fever reducer. It is better known under the names Dipyrone, Analgin, Novalgin, and Melubrin.
Metamizole was first synthesized by the German company Hoechst AG (now part of Sanofi-Aventis) in 1920, and its mass production started in 1922. It remained freely available worldwide until the 1970s, when it was discovered that the drug carries a small risk of causing agranulocytosis - a very dangerous and potentially fatal condition. Controversy remains regarding the level of risk. Several national medical authorities have banned metamizole either totally or have restricted it to be available only on prescription.
Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects.
As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.
Propacetamol is a prodrug form of paracetamol which is formed from esterification of paracetamol, and the carboxylic acid Diethylglycin. This has the advantage of making it more water soluble. It is used in post-operative care and is delivered by I.V.  It is given if the patient is unable to take oral or rectally delivered paracetamol and non-steroidal anti-inflammatory drugs are contraindicated. The onset of analgaesia from propacetamol is more rapid than paracetamol is given orally. 2g of propacetamol are equivalent to 1g of paracetamol.
Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It was introduced to the market by Pfizer in 1991. Sertraline is primarily used to treat clinical depression in adult outpatients as well as obsessive-compulsive, panic and social anxiety disorders in both adults and children. In 2007 it was the most prescribed antidepressant on the U.S. retail market with 29,652,000 prescriptions.